According to filings with the U.S. Securities and Exchange Commission, Vedana Therapeutics has raised $46,000,000.00 in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Westlake BioPartners, Canaan Partners, Dawn Biopharma and Alexandria Venture Investments.

About Vedana Therapeutics
Vedana Therapeutics is a biotechnology company developing next-generation, preventive therapies for migraine by leveraging pituitary adenylate cyclase-activating polypeptide (PACAP) biology, and highly selective combinatorial targeting of clinically validated pathways. Vedana is led by a team of world-renowned experts in migraine drug development and is advancing a portfolio of antibody-based therapies designed to address the significant unmet need in migraine treatment.

To learn more, visit https://vedanatx.com/
Linkedin: https://www.linkedin.com/company/vedana-therapeutics/

Contact:
Anurag Agarwal, Chief Executive Officer
https://www.linkedin.com/in/anurag-agarwal-58a71939/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.